Mechanism of Flavivirus RNA Capping

黄病毒RNA加帽机制

基本信息

批准号：
10308030
负责人：
Brian Geiss
金额：
$ 37.5万
依托单位：
COLORADO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-01-01 至 2023-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10308030
关键词：
3&apos Untranslated Regions 5&apos Untranslated Regions Active Sites Address Affect Antiviral Agents Attention Binding Biochemical Biochemical Reaction Biological Assay Cells Cessation of life Clinical Conserved Sequence Culicidae Data Dengue Development Disease Drug Targeting Elements Enzymes Exonuclease Exoribonucleases Family Flavivirus Flavivirus Infections Genome Goals Guanosine Monophosphate Guanosine Triphosphate Human Immune Evasion Immune response Infection Innate Immune Response Insecta Interferons Knowledge Mediating Methyltransferase Molecular Morbidity - disease rate Mutagenesis Mutate N-terminal Neurologic Pathway interactions Patients Peptides Play Population Process Production Protein Biosynthesis Proteins Public Health RNA RNA Caps RNA Decay RNA Degradation RNA Interference RNA Sequences RNA Stability RNA Viruses RNA replication Reaction Role Series Site Specificity Structure Substrate Specificity Testing Therapeutic Translations Untranslated RNA Urbanization Vaccines Viral Viral Genome Viral Hemorrhagic Fevers Viral Proteins Virion Virus Virus Diseases Virus Replication West Nile virus ZIKA Zika Virus antiviral drug development base climate change combat design experimental study genomic RNA guanylate guanylyltransferase human pathogen improved infection risk insight mRNA Decay mRNA guanylyltransferase member mortality mosquito-borne mutant novel nucleotidyltransferase prevent public health relevance response spleen exonuclease stem trend vaccine access vaccine development viral RNA

项目摘要

Approximately 2/3rd of the world population is at risk of infection by at least one of the 35 insect-borne flaviviruses known to cause disease in humans. There are currently few vaccines and no therapeutics available to treat patients infected by flaviviruses such as Dengue, Zika, and West Nile viruses despite the severe morbidity and mortality they cause globally each year. The development of improved vaccines and therapeutics to prevent and treat flavivirus infections requires improved knowledge of the molecular mechanisms these serious human pathogens use to replicate their genomes. RNA capping of flavivirus genomes has received increasing attention over the last decade as an antiviral drug target due to its critical roles in maintaining viral RNA stability, controlling viral protein translation, and innate immune evasion. There is, however, not much known about how flavivirus RNAs are capped during infection. Therefore, this proposal will define how flaviviruses cap their RNA genomes during infection and evaluate how capping affects innate immune evasion. 1) The NS5 RNA guanylyltransferase is a novel flavivirus enzyme with no structural or sequence similarities to any other known nucleotidyltransferase enzyme. It is currently unknown how this important viral enzyme functions, which is a critical gap in our understanding of flavivirus RNA replication. We are using a combination mutagenesis and viral replication experiments to define the active site of the flavivirus NS5 guanylyltransferase, providing the first in-depth characterization of this unique viral replication enzyme. 2) The 5' untranslated region (UTR) of the flavivirus genome contains conserved sequence and structural elements known to be involved in RNA replication, but their role in RNA capping has never been assessed. We will use a series of mutated 5' UTR RNAs to test the specificity of NS5-mediated RNA capping to define how 5' UTR terminal sequences and the stem-loop A structure affect binding and capping efficiency. 3) Degradation of flavivirus genomes by the cellular RNA decay pathway results in the inhibition of RNA decay and RNAi pathways, altering the immune response to infection. We wish to test the intriguing hypothesis that viral capping efficiency may be strategically regulated by viruses to produce non-coding RNAs that alter infection dynamics. Interestingly, we have recently found that uncapped viral RNAs are incorporated into virus particles and may comprise up to a third of viral RNAs in an infected cell. This surprisingly high level of uncapped RNA is likely processed by RNA decay factors and leads to high levels of a small sfRNA which has been shown previously to antagonize RNAi and interferon responses (among other things). We will examine, therefore, how NS5 capping efficiency affects viral RNA production, the fate of uncapped viral RNAs in cells, and how the products of these uncapped RNAs influence the dynamics of a flavivirus infection. Overall, this project will significantly advance our understanding of flavivirus replication mechanisms that we can exploit for antiviral and vaccine development, and will provide critical new information about how flaviviruses cause disease.

大约2/3的世界人口有35种昆虫传播的人有感染的风险已知会引起人类疾病的黄病毒。目前几乎没有疫苗，没有可用的治疗方法治疗受到黄病毒感染的患者，例如登革热，寨卡病毒和西尼罗河病毒它们每年在全球造成的发病率和死亡率。改进的疫苗和治疗剂的开发为了预防和治疗黄病毒感染需要提高对分子机制的了解严重的人类病原体用于复制其基因组。黄病毒基因组的RNA上限已接收由于其在维持病毒方面的关键作用，在过去十年中，在过去十年中，人们的注意力越来越多 RNA稳定性，控制病毒蛋白翻译和先天免疫逃避。但是，没有什么知道在感染过程中如何限制黄素RNA。因此，该建议将定义如何黄病毒在感染过程中限制其RNA基因组，并评估封盖如何影响先天免疫逃避。 1）NS5 RNA Guanylyllansferase是一种新型黄病毒酶，没有结构或序列相似性任何其他已知的核苷转移酶。目前尚不清楚这种重要的病毒酶如何功能，这是我们对黄病毒RNA复制的理解的关键差距。我们正在使用组合诱变和病毒复制实验，以定义黄素NS5的活性位点 Guanylyltransferase，提供了这种独特的病毒复制酶的第一个深入特征。 2）黄病毒基因组的5'未翻译区（UTR）包含保守的序列和结构已知与RNA复制有关的元素，但它们在RNA封盖中的作用从未得到评估。我们将使用一系列突变的5'UTR RNA来测试NS5介导的RNA盖的特异性，以定义5'的方式 UTR末端序列和茎环A结构会影响结合和封盖效率。 3）退化细胞RNA衰变途径的黄素基因组的抑制作用导致RNA衰变和RNAi的抑制途径，改变了对感染的免疫反应。我们希望检验病毒的有趣假设封盖效率可能会受到病毒的策略调节，以产生改变感染的非编码RNA 动力学。有趣的是，我们最近发现，未覆盖的病毒RNA被纳入病毒颗粒并且可能构成感染细胞中病毒RNA的三分之一。这种令人惊讶的高水平的无盖RNA 可能是由RNA衰减因子处理的，并导致高水平的小SFRNA，已显示以前是对抗RNAi和干扰素反应（除其他事项）。因此，我们将检查 NS5上限效率如何影响病毒RNA的产生，细胞中未覆盖的病毒RNA的命运以及如何这些无盖RNA的产物会影响黄素感染的动力学。总体而言，这个项目将显着提高了我们对可以利用抗病毒物的黄病毒复制机制的理解和疫苗开发，并将提供有关黄病毒如何引起疾病的关键新信息。

项目成果

期刊论文数量（16）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Identification of small molecule inhibitors of the Chikungunya virus nsP1 RNA capping enzyme.

DOI：
10.1016/j.antiviral.2018.03.013
发表时间：
2018-06
期刊：
Antiviral research
影响因子：
7.6
作者：
Feibelman KM;Fuller BP;Li L;LaBarbera DV;Geiss BJ
通讯作者：
Geiss BJ

Kunjin Virus, Zika Virus, and Yellow Fever Virus Infections Have Distinct Effects on the Coding Transcriptome and Proteome of Brain-Derived U87 Cells.

DOI：
10.3390/v15071419
发表时间：
2023-06-23
期刊：
Viruses
影响因子：
0
作者：
Brand C;Deschamps-Francoeur G;Bullard-Feibelman KM;Scott MS;Geiss BJ;Bisaillon M
通讯作者：
Bisaillon M

Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.